Asset Management One Co. Ltd. Has $22.24 Million Holdings in DexCom, Inc. $DXCM

Asset Management One Co. Ltd. increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 254,785 shares of the medical device company’s stock after purchasing an additional 1,430 shares during the period. Asset Management One Co. Ltd. owned approximately 0.06% of DexCom worth $22,240,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Golden State Wealth Management LLC grew its stake in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom during the first quarter worth $27,000. Anderson Financial Strategies LLC acquired a new stake in shares of DexCom during the first quarter worth $37,000. Private Trust Co. NA grew its stake in shares of DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after purchasing an additional 335 shares during the period. Finally, Horizon Financial Services LLC acquired a new stake in shares of DexCom during the first quarter worth $56,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Down 1.0%

NASDAQ:DXCM opened at $70.33 on Friday. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The stock has a market cap of $27.58 billion, a price-to-earnings ratio of 48.84, a PEG ratio of 1.48 and a beta of 1.47. The stock has a 50-day moving average price of $72.37 and a two-hundred day moving average price of $77.90.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Barclays lifted their price objective on DexCom from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 30th. Piper Sandler set a $100.00 target price on DexCom and gave the company an “overweight” rating in a research note on Tuesday. Morgan Stanley boosted their target price on DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Citigroup decreased their target price on DexCom from $105.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. Finally, Mizuho boosted their target price on DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $97.19.

Insider Transactions at DexCom

In other news, Director Kyle Malady sold 667 shares of the company’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president directly owned 105,223 shares of the company’s stock, valued at $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,849 shares of company stock valued at $564,733 over the last three months. 0.32% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.